Health Condition 1: null- Multiple viral warts
Conditions
Interventions
Intervention1: MMR vaccine: MMR vaccine 0.3 mL
TRESIVAC® (Measles, Mumps and Rubella Vaccine (Live) I.P.) , manufactured by Serum Institute of India, Ltd. freeze-dried is prepared from live attenuate
Sponsors
Medical College Kolkata
Eligibility
Inclusion criteria
Inclusion criteria: i. Patients having clinically diagnosed wart(s). ii. Patients who give their informed consent. iii. Patients not having received any anti-wart treatment in the past 4 weeks iv. Lack of viral diseases such as herpes and/or bacterial infections such as impetigo.
Exclusion criteria
Exclusion criteria: i. Pregnant and lactating women. ii. Any evidence of immunosuppression (eg. HIV infection, organ transplantation, long term steroid use etc.). iii. Any other systemic disease (eg. liver or kidney disorder). iv. Presence of mucosal wart(s). v. Presence of ulcerated or inflamed wart(s). vi. Presence of wart(s) in face proper. vii. Patients who participated in a clinical trial in the last three months. viii. Patients not giving consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the size and total number of lesions- a. Complete removal b. Partial clearance c. No response Timepoint: Baseline, 2, 4, 8, 12, 16, 20, 24, 28 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum for Liver Function Test, Urea, Creatinine, Hemoglobin, Total count, Differential Count, Erythrocyte Sedimentation Rate, Fasting blood sugarTimepoint: Screening visit, 4 weeks | — |
Countries
India
Contacts
Public ContactDr Arini Banerjee
Medical College, Kolkata
Outcome results
None listed